Prospective, Randomized, Double-Masked Study to Evaluate the Effect of Rhopressa Versus Placebo on Intraocular Pressure in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension After Selective Laser Trabeculoplasty

What this Trial Is About

Researchers are evaluating how Rhopressa (netarsudil) ophthalmic solution affects intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG) or ocular hypertension who have undergone selective laser trabeculoplasty (SLT) in both eyes. This study aims to understand if starting Rhopressa after 360 degrees SLT can lower IOP more than SLT alone. The trial is a prospective, randomized, double-masked, placebo-controlled study conducted at a single center with 70 participants. Participants will be randomly assigned to receive either Rhopressa 0.02% ophthalmic solution or artificial tears as a placebo. Both treatments involve applying one drop in each eye every evening. The study duration for each participant is expected to be 6 weeks, with up to 12 weeks allowed if a medication washout period is needed before starting the trial. There are three scheduled visits during the study. During the study, participants will have their IOP measured, focusing on the mean diurnal IOP at 42 days as the primary outcome. Other assessments include monitoring adherence to the eye drop regimen and safety evaluations. This information will help healthcare providers decide on the best treatment approach for patients who have recently undergone 360 degrees SLT and may need additional IOP reduction.

Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT